From: Therapy duration and long-term outcomes in extra-pulmonary tuberculosis
Variable | Hazard ratio (95% CI) | P-value |
---|---|---|
Age (years) | ||
18 – 24 | Referent | |
25 – 34 | 2.75 (0.60, 12.59) | 0.19 |
35 – 44 | 2.08 (0.46, 9.44) | 0.34 |
45 – 54 | 2.42 (0.54, 10.85) | 0.25 |
55 – 64 | 2.02 (0.42, 9.66) | 0.38 |
65 – 74 | 3.71 (0.77, 17.79) | 0.10 |
>75 | 7.43 (1.54, 35.93) | 0.01 |
HIV-infected versus non-infected | 2.16 (1.22, 3.83) | <0.01 |
Male | 1.52 (1.01, 2.72) | 0.04 |
TB disease site | ||
Meningeal | Referent | |
Lymphatic | 0.50 (0.27, 0.91) | 0.02 |
Bone/joint | 0.42 (0.21, 0.81) | 0.01 |
Peritoneal | 0.59 (0.27, 1.31) | 0.20 |
Other sites | 0.47 (0.23, 0.97) | 0.04 |
Therapy duration | ||
6-months | Referent | |
<6-months | 2.72 (1.34, 5.50) | <0.01 |
7 – 10 months | 1.63 (0.85, 3.12) | 0.14 |
>10-months | 1.52 (0.75, 3.10) | 0.25 |